GAEC1 (gene amplified in oesophageal cancer 1) is located at 7q22.1, first identified in oesophageal cancer. 1 Initial work indicated that GAEC1 can act as an oncogene. 2 Our pilot study found ∼80% of colorectal cancers showing amplification of GAEC1. 3 In this research, we will study GAEC1 copy number in colon cancer cell lines and colorectal tissues, and its prognostic significance.
Two human colon cancer cell lines (SW480 and SW48) and one normal colonic epithelial cell line (FHC) were obtained from American Type Culture Collection. Culturing conditions for these cell lines were as published previously. 4 Tissues were collected from 283 patients (213 Australian; 70 Japanese) diagnosed with colorectal cancers. Ninety surgically removed non-cancer colorectal tissues (diverticular diseases, hyperplastic polyps and volvulus) were used as controls. H&E stained sections from each cancer were checked to select a block with sufficient cancer tissue and representative morphological features for each patient for DNA extraction.
Cancers were staged according to the Union for International Cancer Control (UICC) for TNM (tumour, node and metastasis) classification. 5 Only primary adenocarcinomas were included. Actuarial survival rates of patients were calculated from the date of surgical resection of the colorectal cancers to the date of death or last follow-up. DNA extraction and PCR reactions for GAEC1 copy number were performed as in our previous studies.
3 4 A ΔCt of <−1 was considered as gain of GAEC1 copies, Ct value >1 was considered as reduced GAEC1 copies and a Ct between these ranges was defined as normal/no change in GAEC1 copies.
GAEC1 DNA was detectable in all colon cell lines tested. The colon cancer cell lines (SW480 and SW48) showed reduced GAEC1 copies compared with normal colonic epithelial cells (FHC) (figure 1A). At the tissue level, GAEC1 gene copies were higher in colorectal cancer compared with non-cancer tissues ( p<0.0001; table 1).
In Australian samples, there was no significant correlation between GAEC1 copy number and clinical/pathological parameters (table 2). Japanese patients showed increased percentage of GAEC1 deletion in colorectal cancers with lymph node metastasis compared with cancers without any lymph node metastasis (10% vs 0%, p=0.046) (table 3). GAEC1 deletion was less common in early stage (Stages I and II) colorectal cancers compared with advanced stage (Stages III and IV) cancers in Japanese patients (0% vs 10%, p=0.046) (table 3). In addition, the proportion of cancers with GAEC1 amplification was slightly higher in the Japanese compared with the Australian populations (80% vs 59%). GAEC1 copy number distribution was significantly different, with GAEC1 copy number higher among Japanese cancers compared with Australian (p=0.003).
Median follow-up period for Australian and Japanese patients was 5 years. Survival data was available in 188 Australian patients (134 survived and 54 died of cancer). Among Japanese patients, 64 patients had follow-up data (43 patients survived and 21 died of cancer). Kaplan-Meier analysis indicated that mean survival of Australian and Japanese patients with colorectal cancer depended on pathological stage of cancer (p<0.0001). For Australian and Japanese patients with colorectal cancer, patients with high GAEC1 copies had longer survival compared with patients with low/ Figure 1 (A) Changes in GAEC1 copy number variation in colon cancer cell lines. Inverse ratio of GAEC1 versus HBD (control) (ct amplification ratio) was used to represent GAEC1 DNA levels in different cell lines. Cancer cell lines (SW480 & SW48) showed lower copies of GAEC1 DNA compared with normal epithelial cell line (FHC). (B and C) Correlation of GAEC1 copy number changes and patients' survival. Australian (B) and Japanese (C) patients diagnosed with colorectal cancers showed better prognosis when they had high GAEC1 copy numbers at the tissue level. On the contrary, patients with cancer having low GAEC1 copy number showed poorer prognosis than other patients. These findings were statistically significant in Australian ( p=0.05) and Japanese populations ( p=0.02).
normal GAEC1 copies (Australians: mean survival time-71 months vs 49 months, p=0.05; Japanese: mean survival time-60 months vs 30 months, p=0.02; figure 1B,C) .
In this study, Japanese patients showed a higher percentage of GAEC1 amplification and fewer low copy number samples than Australian patients with colorectal cancer. This difference may reflect a real variance in characteristics or causes of colorectal cancer in the two populations. Also, these changes in GAEC1 could be related to different environmental and genetic factors in these populations. Further studies on these parameters in conjunction with GAEC1 may be helpful in identifying exactly what forces are behind these differences. Japanese patients with colorectal cancer showed correlations between GAEC1 copy number with pathological stages and presence of lymph node metastasis, with high GAEC1 copies in cancers with earlier pathological stages or no lymph node metastasis. The findings imply that GAEC1 may function more in early stages of colorectal cancer progression. At later pathological stages, GAEC1's oncogenic roles may be carried on to potential interactors in molecular carcinogenesis. Further experiments including matched primary and lymph node metastases in the same patient would help in understanding this phenomenon.
This study is the first to investigate the prognostic role of GAEC1 in patients with colorectal cancer. In Australian and Japanese patients with colorectal cancer, increased GAEC1 copy number was correlated with a longer survival time. This may indicate that patients with low GAEC1 copies have more aggressive cancer, perhaps related to the association to pathological stage and lymph node metastasis seen in the Japanese patients. This finding supports the notion that GAEC1 plays a role in cancer initiation rather than cancer progression.
In contrast with tissues, GAEC1 showed loss of DNA copies in the colon cancer cell lines compared with normal colon cell lines. In cell lines, genes are less tightly regulated and they are genetically more complex than those in tissues. 6 Studies have also proven that ex vivo culture conditions can result in the attainment of genomic modification that may not show in the in vivo situation. 7 Thus, the difference in GAEC1 copies could be due to environmental alterations in cell lines compared with solid cancer tissues. This phenomenon may indicate that GAEC1 loses copies when cancer cells are more viable. This can be attributed to the factors influencing GAEC1 deletion in lymph node metastases and cancer with poor patient prognosis. Take-home messages ▸ GAEC1 copy number altered significantly between patients with cancer and the normal population. ▸ GAEC1 amplification was noticed in the cancer population and amplification of GAEC1 was different in patients with cancer from distinctive ethnic backgrounds. ▸ GAEC1 amplification was associated with negative lymph node metastasis and earlier pathological stages in the Japanese population. ▸ GAEC1 amplification in colorectal cancer was associated with better prognosis.
